GLEN ALLEN, Va., Sept. 20, 2011 /PRNewswire/ — Rock Creek
Pharmaceuticals, a subsidiary of Star Scientific, Inc. (NASDAQ:
CIGX), announced that on September 19, 2011 a utility patent
application was filed with the Patent and Trademark Office (“PTO”).
This utility patent application is based on several
previously-filed provisional applications, and it is directed to
various products containing anatabine and the administration of
anatabine to reduce inflammation. Anatabine has the potential to be
particularly useful for nutritional support for disorders involving
inflammation that is associated with Nuclear Factor-KappaB (NF-kB)
mediated transcription. NF-kB is a transcription factor that
operates in cells and participates in the immune response. NF-kB
mediated transcription is associated with numerous disorders,
including those with inflammatory components, abnormal immune
response and/or inappropriate cell proliferation. NF-kB is
associated with over 200 inflammatory pathways.
(Logo:
http://photos.prnewswire.com/prnh/20090317/STARSCIENTIFICLOGO)
Rock Creek Pharmaceuticals has developed a dietary supplement,
Anatabloc™, that contains anatabine citrate as well as
Vitamins A & D3, which was launched on August 30. This is the
second dietary supplement developed by the company: CigRx®, the
first product, was introduced in August, 2010. CigRx® is a
non-nicotine, non-tobacco alternative for smokers that reduces the
urge to light a cigarette, and it contains both anatabine citrate
and yerba mate. It is believed that this combination of dietary
ingredients mimics the brain activity that occurs when nicotine is
inhaled. It is available for purchase via a dedicated product
website (www.cigrx.com) or the Amazon.com
purchase portal. CigRx also is available at all CVS-Pharmacy stores
in the Richmond, VA area, and in roug
‘/>”/>
